Guy Bormans Selected Research

MK-6240

1/2020

Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Guy Bormans Research Topics

Disease

28	Neoplasms (Cancer) 01/2022 - 03/2006
14	Alzheimer Disease (Alzheimer's Disease) 12/2022 - 03/2009
12	Necrosis 01/2022 - 08/2005
11	Neuroinflammatory Diseases 01/2020 - 01/2014
11	Parkinson Disease (Parkinson's Disease) 10/2019 - 11/2006
7	Schizophrenia (Dementia Praecox) 01/2017 - 01/2013
6	Pain (Aches) 01/2018 - 04/2010
5	Inflammation (Inflammations) 10/2019 - 03/2007
5	Huntington Disease (Huntington's Disease) 12/2014 - 09/2010
4	Alcoholism (Alcohol Abuse) 01/2022 - 02/2014
4	Cognitive Dysfunction 01/2022 - 08/2007
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 09/2019
3	Central Nervous System Diseases (CNS Diseases) 10/2021 - 07/2011
3	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 08/2017
3	Rhabdomyosarcoma 01/2020 - 02/2009
3	Tauopathies 01/2020 - 06/2015
3	Primary Progressive Aphasia 01/2020 - 01/2017
3	Anorexia Nervosa 02/2014 - 03/2007
3	Obesity 01/2014 - 01/2008
3	Neurogenic Inflammation 11/2013 - 01/2013
3	Hepatic Infarction 01/2011 - 11/2007
3	Infarction (Infarctions) 01/2008 - 01/2006
3	Myocardial Infarction 01/2008 - 08/2005
2	Mental Disorders (Mental Disorder) 01/2022 - 05/2010
2	Neoplasm Metastasis (Metastasis) 04/2021 - 01/2020
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 08/2012
2	Melanoma (Melanoma, Malignant) 07/2019 - 01/2019
2	Atrophy 01/2018 - 01/2017
2	Pulmonary Arterial Hypertension 12/2017 - 02/2014
2	Amyloidosis 11/2016 - 08/2009
2	Anorexia 02/2014 - 10/2011
2	Feeding and Eating Disorders (Eating Disorder) 02/2014 - 10/2011
2	Hypersensitivity (Allergy) 07/2010 - 05/2007
1	Infections 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2021
1	medullary Thyroid cancer 01/2021

Drug/Important Bio-Agent (IBA)

12	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2022 - 06/2008
9	EndocannabinoidsIBA 01/2018 - 03/2008
6	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2022 - 01/2013
6	Biomarkers (Surrogate Marker)IBA 10/2021 - 08/2009
6	LigandsIBA 09/2020 - 04/2007
6	Ethanol (Ethyl Alcohol)IBA 02/2014 - 07/2007
6	hypericinIBA 12/2012 - 12/2003
5	Pharmaceutical PreparationsIBA 01/2022 - 03/2013
5	Radioisotopes (Radionuclides)IBA 04/2021 - 07/2010
5	Amyloid (Amyloid Fibrils)IBA 01/2020 - 08/2007
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2014
5	Purinergic P2X7 ReceptorsIBA 01/2020 - 01/2016
5	N,N- diethyl- 2- (2- (4- (2- fluoroethoxy)phenyl)- 5,7- dimethylpyrazolo(1,5- a)pyrimidin- 3- yl)acetamideIBA 10/2019 - 10/2015
5	CannabinoidsIBA 01/2019 - 01/2008
5	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 02/2014 - 02/2010
4	fosbretabulin (combretastatin A4)IBA 01/2020 - 09/2011
4	Biological ProductsIBA 10/2015 - 11/2007
4	salicylhydroxamic acid (SHAM)IBA 11/2012 - 05/2007
3	Amyloid beta-PeptidesIBA 01/2022 - 03/2009
3	EnzymesIBA 01/2022 - 01/2013
3	Contrast MediaIBA 01/2020 - 08/2005
3	Metabotropic Glutamate 5 ReceptorIBA 01/2020 - 12/2015
3	LipopolysaccharidesIBA 12/2018 - 10/2015
3	Guanosine Monophosphate (5' Guanylic Acid)IBA 12/2017 - 01/2014
3	SolutionsIBA 10/2015 - 03/2006
3	Pentetic Acid (DTPA)FDA LinkGeneric 06/2013 - 11/2007
3	Oxidopamine (6 Hydroxydopamine)IBA 02/2010 - 11/2006
2	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 01/2022 - 01/2020
2	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 10/2021 - 01/2020
2	Therapeutic UsesIBA 01/2021 - 10/2015
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2021 - 11/2016
2	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2020 - 01/2018
2	Gallium-68IBA 01/2020 - 07/2010
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2020 - 01/2018
2	Levodopa (L Dopa)FDA LinkGeneric 10/2019 - 03/2012
2	Phosphates (Orthophosphate)IBA 07/2018 - 08/2017
2	Dihydrotachysterol (AT 10)IBA 07/2018 - 08/2017
2	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 12/2017 - 02/2014
2	2- oxo- 7- methoxy- 8- butyloxy- 1,2- dihydroquinoline- 3- carboxylic acid cyclohexylamideIBA 11/2016 - 08/2013
2	CationsIBA 04/2013 - 01/2013
2	IodineIBA 07/2012 - 09/2011
2	pamoic acidIBA 07/2010 - 11/2007
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 03/2007 - 01/2005
1	Muscarinic M4 ReceptorIBA 12/2022
1	Dopamine (Intropin)FDA LinkGeneric 01/2022
1	Apolipoproteins E (ApoE)IBA 01/2022
1	ApolipoproteinsIBA 01/2022
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 10/2021
1	68Ga-pentixaforIBA 10/2021
1	plerixafor FDA Link 10/2021
1	1,10- phenanthroline- platinum(II)- ethylenediamine (PEPT)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Proto-Oncogene Proteins c-metIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Tyrosine (L-Tyrosine)FDA Link 01/2021
1	2- (4- (3- quinolin- 6- ylmethyl- 3H- (1,2,3)triazolo(4,5- b)pyrazin- 5- yl)pyrazol- 1- yl)ethanolIBA 01/2021
1	cabozantinibIBA 01/2021
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 09/2020
1	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 09/2020

Therapy/Procedure

13	Therapeutics 01/2022 - 01/2005
5	Drug Therapy (Chemotherapy) 01/2020 - 07/2003
3	Aftercare (After-Treatment) 01/2020 - 03/2007
2	Gastric Balloon 10/2013 - 05/2007
1	Proton Therapy 04/2021